Evidence map›Paper›PMID 32085846›Full record

ArticleThe Lancet. Respiratory medicine2020

Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Zhe Xu, Lei Shi, Yijin Wang, Jiyuan Zhang, Lei Huang, Chao Zhang, Shuhong Liu, Peng Zhao, Hongxia Liu, Li Zhu and 8 more

Erratum issued 24 registry-linked trialsAbstract readCase Reports
In one paragraph

Article in The Lancet. Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 24 registered trials, which are not on this map. Cited by 4,766 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4,766citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04290858 phase2withdrawnnot on this map

Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID19 Infection: a Randomized Clinical Trial

TypeinterventionalSponsorXijing HospitalRan2020 to 2022Enrolled0ConditionsCoronavirus Infections, Pneumonia, Viral, DyspneaArmsNitric Oxide
NCT04290871 phase2withdrawnnot on this mapstarted 2023, after this paper: background citation

Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.

TypeinterventionalSponsorXijing HospitalRan2023 to 2024Enrolled0ConditionsCoronavirus Covid-19 Infection Variant Omicron, SARS (Severe Acute Respiratory Syndrome)ArmsNitric Oxide Gas, The delivery system will be set up anyway without study gas administration
NCT04332913 unknown statusnot on this map

Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study

TypeobservationalSponsorUniversity of L'AquilaRan2020 to 2021Enrolled30ConditionsCOVID-19 Pneumonia
NCT04341688 naunknown statusnot on this mapstarted 2021, after this paper: background citation

A Double Blind, Randomized Controlled Pilot Trial of Gargling Agents in Reducing Intraoral Viral Load Among Laboratory Confirmed COVID-19 Patients: GARGLES STUDY

TypeinterventionalSponsorAga Khan UniversityRan2021 to 2022Enrolled50ConditionsCovid-19ArmsGargle/Mouthwash
NCT04349592 nacompletednot on this map

Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19

TypeinterventionalSponsorHamad Medical CorporationRan2020 to 2020Enrolled456ConditionsCovid19ArmsHydroxychloroquine, Azithromycin, Placebo Tablet, Placebo capsules
NCT04350580 phase3completednot on this map

Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections

TypeinterventionalSponsorCentre Hospitalier St AnneRan2020 to 2021Enrolled146ConditionsAcute Respiratory Distress Syndrome, COVID-19ArmsHuman immunoglobulin, Placebo
NCT04378712 nacompletednot on this map

Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial

TypeinterventionalSponsorGuangzhou Institute of Respiratory DiseaseRan2020 to 2020Enrolled90ConditionsCovid-19, Hydrogen/Oxygen Mixed Gas, DyspneaArmsHydrogen Oxygen Generator with Nebulizer, Standard-of-care
NCT04380935 phase2 / phase3unknown statusnot on this map

Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia

TypeinterventionalSponsorIndonesia UniversityRan2020 to 2020Enrolled60ConditionsCOVID, Acute Respiratory Distress SyndromeArmsConvalescent plasma, Standard of care
NCT04397172 terminatednot on this map

Characterization of ARDS, Critical Illness Myopathy and Their Long-term Consequences in Patients With Covid-19 Disease: Effects of Inflammation, Mitochondrial Dysfunction and Plasma Concentrations of Various Sedative Drugs

TypeobservationalSponsorInsel Gruppe AG, University Hospital BernRan2020 to 2023Enrolled48ConditionsCOVID, Corona Virus Infection, Sars-CoV2ArmsStudy Arm
NCT04400929 phase2completednot on this map

Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial

TypeinterventionalSponsorSingapore General HospitalRan2020 to 2022Enrolled2ConditionsCOVID, Sars-CoV2, ARDS, HumanArmsSargramostim, Normal Saline 0.9%
NCT04420260 nacompletednot on this mapstarted 2021, after this paper: background citation

Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia

TypeinterventionalSponsorUnidad de Investigación Genética MolecularRan2021 to 2021Enrolled152ConditionsCOVIDArmsGroup A: oropharygeal spray and immunostimulant emulsion, Group D:Placebo oropharyngeal spray + Placebo taken PO
NCT04534803 phase3withdrawnnot on this mapstarted 2021, after this paper: background citation

Bacillus Calmette-Guerin Against Covid-19 for Prevention and Amelioration of Severity Trial

TypeinterventionalSponsorHarvard Medical School (HMS and HSDM)Ran2021 to 2022Enrolled0ConditionsCovid19ArmsBCG Vaccine, Placebo
NCT04559113 naunknown statusnot on this map

Perks of Methylprednisolone for Hospitalized COVID-19 Patients: A Clinical Trial

TypeinterventionalSponsorLahore General HospitalRan2020 to 2020Enrolled200ConditionsSARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome)ArmsMethylprednisolone Injectable Product
NCT04753762 completednot on this map

Multimodal IMAgery (Echocardiography and Cardiac MRI) Characterization of Cardiac Damage and Severity After COVID-19 Infection

TypeobservationalSponsorCentral Hospital, Nancy, FranceRan2020 to 2022Enrolled50ConditionsCOVID-19 Virus Disease, Cardiac Complication
NCT04836767 completednot on this mapstarted 2021, after this paper: background citation

Evaluation of Exercise Capacity, Peripheral Muscle Strength, Balance, Cognitive Status and Quality of Life in Patients With COVID-19 in Long Term

Typeobservational_patient_registrySponsorHacettepe UniversityRan2021 to 2022Enrolled40ConditionsCorona Virus Infection, Covid19
NCT04847375 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Evaluation of the Effect of Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients

TypeinterventionalSponsorShahid Beheshti University of Medical SciencesRan2021 to 2021Enrolled60ConditionsCOVID-19, Respiratory Distress Syndrome, Surface-Active AgentsArmsexogenous surfactant
NCT04854941 nacompletednot on this map

Efficacy of Probiotics (Lactobacillus Rhamnosus, Bifidobacterium Bifidum, Bifidobacterium Longum Subsp. Infantis and Bifidobacterium Longum) in the Treatment of Hospitalised Patients With Novel Coronavirus Infection

TypeinterventionalSponsorI.M. Sechenov First Moscow State Medical UniversityRan2020 to 2021Enrolled200ConditionsCoronavirus InfectionArmsProbiotics
NCT04869579 phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients

TypeinterventionalSponsorCHRISTUS HealthRan2021 to 2021Enrolled100ConditionsCovid19ArmsSelenium (as Selenious Acid), Placebo
NCT05043129 unknown statusnot on this mapstarted 2021, after this paper: background citation

Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection

TypeobservationalSponsorThe Second Affiliated Hospital of Chongqing Medical UniversityRan2021 to 2022Enrolled200ConditionsHIV Infections, Covid19ArmsBiological/Vaccine: SARS-COV-2 VACCINE
NCT05060354 completednot on this mapstarted 2021, after this paper: background citation

Immune Response to SARS-CoV2 Vaccinations in Treated MS Patients Compared to Controls

TypeobservationalSponsorBrigham and Women's HospitalRan2021 to 2023Enrolled159ConditionsMultiple Sclerosis, HealthyArmsBlood draw
NCT05132972 phase2 / phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Efficacy and Safety of Normoxic Allogenic Umbilical Cord Mesenchymal Stem Cells Administered as Adjuntive Treatment to Standard Treatment in Severe Patients With COVID-19

TypeinterventionalSponsorKementerian Riset dan Teknologi / Badan Riset dan Inovasi Nasional, IndonesiaRan2021 to 2021Enrolled42ConditionsCovid 19ArmsNormoxic Allogenic UCMSC, Normal saline solution
NCT05304702 completednot on this mapstarted 2021, after this paper: background citation

Lung Injury (Pulmonary Edema) in COVID-19: Treatment With Furosemide and Negative Fluid Balance (NEGBAL): a Case-Control Study

TypeobservationalSponsorClinica ColonRan2021 to 2022Enrolled120ConditionsCOVID-19
NCT05721144 phase2completednot on this mapstarted 2023, after this paper: background citation

Inhaled NO ReDuce postoperatIve pulmoNAry complicATions in patiEnts With Recent COVID-19 Infection

TypeinterventionalSponsorXijing HospitalRan2023 to 2024Enrolled660ConditionsNitric Oxide, COVID-19, Surgery, Postoperative ComplicationsArmsNitric Oxide Gas
NCT05741099 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

The Application and Research of Mesenchymal Stem Cells in Alleviating the Severe Development of Novel Coronavirus Infection to Clarify Its Safety and Effectiveness.

TypeinterventionalSponsorHebei Medical UniversityRan2023 to 2025Enrolled20ConditionsCOVID-19ArmsUmbilical cord mesenchymal stem cells implantation, Comparator
3 · Its place in the literature

Who cites it

4,766 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Investigating the Short-Term Changes of the Electrocardiogram Indicators During Hospitalization in Patients With COVID-19 Following the Use of Tocilizumab.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

4,706 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Zhe XuTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Lei ShiTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Yijin WangDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Jiyuan ZhangTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Lei HuangTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Chao ZhangTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Shuhong LiuDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Peng ZhaoTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Hongxia LiuTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Li ZhuDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Yanhong TaiDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Changqing BaiDepartment of Respiration, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Tingting GaoDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Jinwen SongTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Peng XiaTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Jinghui DongDepartment of Radiology, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Jingmin ZhaoDepartment of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China. Electronic address: jmzhao302@163.com.
Fu-Sheng WangTreatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China. Electronic address: fswang302@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID32085846
PMCPMC7164771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 18 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.